Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boostrix-GlaxoSmithKline-Shigellosis
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Boostrix-GlaxoSmithKline-Shigellosis is a misnomer for the investigational vaccine candidate **1790GAHB** (also known as **GVGH 1790GAHB**), developed by the **GSK Vaccines Institute for Global Health (GVGH)**. The name appears to be a concatenation of the control vaccine (Boostrix), the developer (GSK), and the target indication (Shigellosis) from clinical trial contexts. 1790GAHB is a vaccine designed to prevent **shigellosis** caused by *Shigella sonnei*. It utilizes **Generalized Modules for Membrane Antigens (GMMA)** technology, which involves outer membrane vesicles shed by genetically modified bacteria that overexpress the **O-antigen (OAg)** portion of the **lipopolysaccharide (LPS)**. The vaccine is formulated with **Alhydrogel** (aluminum hydroxide) and administered intramuscularly to induce anti-S. sonnei LPS IgG antibodies. Boostrix itself is a separate GSK vaccine for tetanus, diphtheria, and acellular pertussis and was used as a control in trials for 1790GAHB.
- Other names
- GVGH S. sonnei vaccineShigella sonnei GMMA vaccineGVGH S. sonnei (1790GAHB) vaccine
Beyond the preview
Go deeper on Boostrix-GlaxoSmithKline-Shigellosis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boostrix-GlaxoSmithKline-Shigellosis.